CRC Research Finding
Skip to content
The CRC Digest
Dihydroartemisinin targets KRASG12D to overcome immunotherapy resistance
Anti-malaria drug selectively downregulates KRASG12D mutant protein and enhances regorafenib plus anti-PD-1 in preclinical liver metastasis models. (Cell Death & Disease)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or